Radioactive tracer could reveal breast Cancer's inner workings
NCT ID NCT02284919
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tests a new radioactive tracer called [18F]ISO-1 in PET scans for people with breast cancer. The tracer targets sigma-2 receptors, which are linked to how fast cancer cells multiply. Researchers want to see if the scan can measure tumor growth rates and help guide treatment decisions. The study involves 30 adults with known or suspected breast cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
[18F]ISO-1, a radioactive tracer used in PET scans
What this could lead to
If successful, this could lead to a new imaging method to better detect breast cancer and measure how fast tumors are growing without needing a biopsy.
What could go wrong
This is an early phase 1 study with only 30 participants, so the tracer may not reliably distinguish cancer from normal tissue or may have safety issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Pennsylvania Hospital
Philadelphia, Pennsylvania, 19104, United States